Bookmark This Page | E-mail This Page | Print This Page

Prostate Cancer Products

Through the development of hormonal approaches to prostate cancer treatment, represented by CASODEX and ZOLADEX, AstraZeneca has helped provide care for patients with prostate cancer across the continuum. Learn more about our products for prostate cancer treatment.

CASODEX

CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of Stage D2 metastatic carcinoma of the prostate.

CASODEX 150 mg daily is not approved for use alone or with other treatments.

Learn more about CASODEX.

 

ZOLADEX

ZOLADEX 3.6 mg depot and
10.8 mg depot are indicated in the palliative treatment of advanced carcinoma of the prostate.

ZOLADEX 3.6 mg depot and
10.8 mg depot are also indicated for use in combination with flutamide for the management of locally advanced Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with the combination should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

Learn more about ZOLADEX.

 

 
 

Next: CASODEX